Home Cart 0 Sign in  
X

[ CAS No. 189442-87-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 189442-87-3
Chemical Structure| 189442-87-3
Chemical Structure| 189442-87-3
Structure of 189442-87-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 189442-87-3 ]

Related Doc. of [ 189442-87-3 ]

Alternatived Products of [ 189442-87-3 ]

Product Details of [ 189442-87-3 ]

CAS No. :189442-87-3 MDL No. :MFCD08689955
Formula : C14H25NO4 Boiling Point : -
Linear Structure Formula :- InChI Key :ZQZVWDXMUCTNRI-UHFFFAOYSA-N
M.W : 271.35 Pubchem ID :16218276
Synonyms :

Calculated chemistry of [ 189442-87-3 ]

Physicochemical Properties

Num. heavy atoms : 19
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.86
Num. rotatable bonds : 6
Num. H-bond acceptors : 4.0
Num. H-bond donors : 0.0
Molar Refractivity : 76.85
TPSA : 55.84 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.41 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.44
Log Po/w (XLOGP3) : 2.18
Log Po/w (WLOGP) : 2.21
Log Po/w (MLOGP) : 1.85
Log Po/w (SILICOS-IT) : 1.93
Consensus Log Po/w : 2.32

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.5
Solubility : 0.859 mg/ml ; 0.00316 mol/l
Class : Soluble
Log S (Ali) : -2.99
Solubility : 0.28 mg/ml ; 0.00103 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.36
Solubility : 1.18 mg/ml ; 0.00435 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.54

Safety of [ 189442-87-3 ]

Signal Word:Danger Class:8,6.1
Precautionary Statements:P261-P280-P301+P310-P305+P351+P338 UN#:2922
Hazard Statements:H301-H315-H318-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 189442-87-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 189442-87-3 ]
  • Downstream synthetic route of [ 189442-87-3 ]

[ 189442-87-3 ] Synthesis Path-Upstream   1~14

  • 1
  • [ 189442-87-3 ]
  • [ 189321-63-9 ]
YieldReaction ConditionsOperation in experiment
92% With lithium hydroxide; water In methanol at 25℃; for 16 h; A mixture of the compound of formula LB (4.1Og, 15.1mmol) and lithium hydroxide (2.17g, 90.6mmol) in methanol (3OmL)ZH2O (2OmL) was stirred at a temperature of about 250C for 16h. After evaporation to dryness, the residue was partitioned between DCM and brine. The organic layer was separated, dried (MgSO4), filtered, and concentrated under reduced pressure to provide 3.38g of the compound of formula LC as a white solid (yield 92.0percent).The identity of the compound of formula LC, l-(teτt-butoxycarbonyl)- 4-methylpiperidine-4-carboxylic acid, was confirmed using 1H NMR and LC/MS.Compound LC: 1H NMR: δH (400 MHz, CDCl3): 3.60-3.70 (2H, m), 3.03-3.09 (2H, m)2.05-2.08 (2H, m), 1.45 (9H, s), 1.36-1.45 (2H, m), 1.27 (3H, m); LC/MS (100percent, tr = 2.500 min), m/z = 266.1 [M + Na]+ (CaIc: 243).
75%
Stage #1: With sodium hydroxide In tetrahydrofuran; methanol at 20℃; for 48 h;
Stage #2: With hydrogenchloride In water
Method W: 1-(tert-butoxycarbonyl)-4-methylpiperidine-4-carboxylic acid
2.0 M sodium hydroxide (20 ml) was added to 1-tert-butyl 4-ethyl 4-methylpiperidine-1,4-dicarboxylate (4 g, 14.76 mmol) in tetrahydrofuran (40 ml) and methanol (5 ml).
The solution was stirred at room temperature for 48 hours.
The reaction mixture was extracted with ethyl acetate.
The aqueous layer was acidified to pH 1-2 with a concentrated solution of HCl.
The acid was extracted with EtOAc.
The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo to afford the desired compound (2.7 g, 75percent yield).
1H NMR (CDCl3, 400 MHz) δ 1.29 (3H, s), 1.36-1.48 (2H, m), 1.47 (9H, s), 2.09 (2H, dt), 3.08 (2H, t), 3.79 (2H, br d).
Reference: [1] Patent: WO2008/89201, 2008, A2, . Location in patent: Page/Page column 234
[2] Patent: US2010/137305, 2010, A1, . Location in patent: Page/Page column 36
[3] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 14, p. 3675 - 3678
[4] Patent: US6083949, 2000, A,
[5] Patent: EP854870, 2009, B1, . Location in patent: Page/Page column 42
[6] Journal of Medicinal Chemistry, 2017, vol. 60, # 11, p. 4680 - 4692
[7] Patent: WO2008/121687, 2008, A2, . Location in patent: Page/Page column 43; 89; 94-95
  • 2
  • [ 7664-93-9 ]
  • [ 189442-87-3 ]
  • [ 189321-63-9 ]
Reference: [1] Patent: US5717100, 1998, A,
  • 3
  • [ 67-56-1 ]
  • [ 189442-87-3 ]
  • [ 189321-63-9 ]
Reference: [1] Patent: US6140333, 2000, A,
  • 4
  • [ 189442-87-3 ]
  • [ 343788-69-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 14, p. 3675 - 3678
  • 5
  • [ 142851-03-4 ]
  • [ 74-88-4 ]
  • [ 189442-87-3 ]
YieldReaction ConditionsOperation in experiment
100% With lithium diisopropyl amide In tetrahydrofuran at -78 - 20℃; for 2.5 h; Inert atmosphere Ethyl N-Boc-piperidine-4-carboxylate (10.00 g, 36.92 mmol) was dissolved in THF(100 mL) and cooled to -78°C. LDA (47 mmol, 23 mL) was added and the reaction stirred for 1 h. Iodomethane (81.25 mmol, 5.08 mL) was then added and the reaction stirred for a further lh before removing the cold bath and allowing the reaction to warm to r.t. for 30 min. The reaction was quenched with NH4C1 (sat) and partitioned with EtOAc, the organics were extracted and dried (MgS04) and concentrated in vacuo, (quantitative yield). 1H NMR (400 MHz, DMSO- d6) δ: 4.11 (q, J 7.1 Hz, 2 H), 3.61 (dt, J 13.4 Hz, J 4.5 Hz, 2 H), 2.95 (d, J 0.3 Hz, 2 H), 1.91 (d, J 13.6 Hz, 2 H), 1.39 (s, 9 H), 1.31 (m, 2 H), 1.19 (m, 3 H), 1.15 (s, 3 H).
100%
Stage #1: With lithium diisopropyl amide In tetrahydrofuran at -78℃; for 1 h;
Stage #2: at 20℃; for 1.5 h;
Ethyl N-Boc-piperidine-4-carboxylate (10.00 g, 36.92 mmol) was dissolved inTHF (100 mL) and cooled to -78°C. LDA (47 mmol, 23 mL) was added and the reactionstirred for 1 h. lodomethane (81.25 mmol, 5.08 mL) was then added and the reaction stirred for a further lh before removing the cold bath and allowing the reaction to warm to r.t. for 30 mm. The reaction was quenched with sat. aq. NH4C1 and partitioned with EtOAc, the organics were extracted and dried (MgSO4) and concentrated in vacuo,(quantitative yield). 1H NMR (400 MHz, DMSO- d6) ö: 4.11 (q, J7.1 Hz, 2 H), 3.61 (dt, J13.4 Hz, J 4.5 Hz, 2 H), 2.95 (d, J 0.3 Hz, 2 H), 1.91 (d, J 13.6 Hz, 2 H), 1.39 (s, 9 H),1.31 (m, 2 H), 1.19 (m, 3 H), 1.15 (s, 3 H).
100%
Stage #1: With lithium hexamethyldisilazane In tetrahydrofuran at -40℃; for 1 h;
Stage #2: at -40 - 20℃; for 14 h;
The compound was prepared following a procedure outlined in PCT Publication No. WO 01/40217. 1-tert-Butyl 4-ethyl piperidine-l,4-dicarboxylate (7.12 g, 27.7 mmol) was dissolved in THF (30 mL) and cooled to -40 °C. LHMDS (55.3 ml, 55.3 mmol) was added slowly and the solution was stirred at -40 °C for 1 hour. Iodomethane (3.45 ml, 55.3 mmol) was added and the reaction mixture was warmed to ambient temperature and stirred for 14 hours. The reaction was quenched with water and saturated NaHCO3. After diluting with methylene chloride, the layers were separated. The aqueous layer was washed twice with methylene chloride, and the combined organic layers were washed with saturated NaCl, dried over Na2SO4 and concentrated in vacuo to provide the desired product as an oil (quantitative). 1H NMR (400 MHz, CDCl3) δ 4.16 (q, 2H), 3.83-3.70 (m, 2H), 3.03-2.94 (m, 2H), 2.11-2.02 (m, 2H), 1.45 (s, 9H), 1.41-1.30 (m, 2H), 1.26 (t, 3H), 1.20 (s, 3H).
76.8%
Stage #1: With n-butyllithium; diisopropylamine In tetrahydrofuran at -78 - 0℃; for 2.75 h;
Stage #2: at -78 - 25℃; for 16 h;
To a mixture of iV,jV-diisopropylamme (6.8ImL, 48.6mmol) in THF (10OmL) at a temperature of O0C was added dropwise a mixture of 1.6N n-butyl lithium (Sigma-Aldrich) in THF (30.4mL, 48.6mmol). The resulting mixture was stirred at O0C for 15 min. After cooling to a temperature of -780C, a mixture of the compound of formula LA (1-tert-butyl 4-ethyl piperidine-l,4-dicarboxylate, 10. Og, 38.9mmol, Sigma-Aldrich) in THF (5OmL) was added dropwise over a 30min period. After being stirred at -780C for 2h, a mixture of methyl iodide (4.84mL, 77.7mmol) in THF (3OmL) was added dropwise at -780C. The mixture was allowed to warm to a temperature of about 250C for 16h. After quenching with saturated aqueousNH4Cl, the mixture was partitioned between THF and saturated aqueous NH4Cl. The organic layer was separated, dried (Na2SO4), filtered, and concentrated under reduced pressure. The product was chromatographed (COMBIFLASH) with a gradient of from 0percent:100percent EtOAc:hexanes to 50percent:50percent EtOAc:hexanes to provide, after concentration under reduced pressure, 8.1Og of the compound of formula LB as a pale yellow solid (yield 76.8percent).The identity of the compound of formula LB, l-tert-buty\\ 4-ethyl 4-methylpiperidine- 1 ,4-dicarboxylate, was confirmed using 1H NMR.Compound LB: 1H NMR: δH (400 MHz, CDCl3): 4.16 (2H, q, J=7.1Hz), 3.76 (2H, br), 2.95-3.01 (2H, m), 2.05-2.08 (2H, m), 1.45 (9H, s), 1.32-1.43 (2H, m), 1.26 (3H, t, J=7. IHz), 1.20 (3H, s).
75%
Stage #1: With lithium diisopropyl amide In tetrahydrofuran at 0℃; for 0.666667 h; Inert atmosphere
Stage #2: at 0 - 20℃; for 5 h;
tert-Butyl 4-ethyl 4-methylpiperidine-1,4-dicarboxylate
To tert-butyl-4-ethyl piperidine-1,4-dicarboxylate (10.03 g, 39.0 mmol), dissolved in THF (50 mL) and cooled to 0° C. in an ice bath under nitrogen, was added dropwise LDA (2M solution in THF; 25.0 mL, 50 mmol).
The mixture was stirred at 0° C. for 40 minutes.
Iodomethane (3.2 mL, 51 mmol) was then added, and the mixture was stirred at 0° C. for 3 h before warming to r.t.
The reaction mixture was left to stand at r.t. for 2 h. EtOAc (150 mL) was added and the mixture was washed with brine (2*100 mL).
The organic layer was separated, dried (Na2SO4), and filtered under reduced pressure.
The solvent was removed in vacuo to yield a brown oil which was purified by flash column chromatography on silica, using 100percent isohexane to 100percent EtOAc, followed by concentration in vacuo, to afford the title compound (7.92 g, 75percent) as an orange oil. δH (300 MHz, DMSO-d6) 4.10 (q, J 7.1 Hz, 2H), 3.60 (dt, J 13.6, 4.4 Hz, 2H), 2.94 (br t, J 11.7 Hz, 2H), 1.95-1.84 (m, 2H), 1.39 (s, 9H), 1.30 (ddd, J 14.0, 10.2, 4.1 Hz, 2H), 1.18 (t, J 7.1 Hz, 3H), 1.14 (s, 3H).
65%
Stage #1: With lithium diisopropyl amide In tetrahydrofuran at -78℃; for 0.75 h;
Stage #2: at -78 - 20℃; for 6 h;
A solution of O1-tert-butyl O4-ethyl piperidine-1,4-dicarboxylate (1.5 g, 5.84 mmol) in THF (25 mL) was cooled to -78° C. followed by dropwise addition of LDA (1.80 M in THF, 6.5 mL, 11.68 mmol) at -78° C. The resulting mixture was stirred at the same temperature for 45 minutes followed by addition of MeI (1.2 mL, 17.52 mmol) at -78° C. The temperature of the reaction mixture was slowly raised up to rt and left to stir at rt for 6 h. The reaction mixture was then cooled to 0° C., quenched by dropwise addition of saturated NH4Cl solution (50 mL) and extracted with EtOAc (3.x.100 mL). The combined organics were washed with brine, dried (Na2SO4), filtered and concentrated under reduced pressure. The crude residue was purified over 100-200 M silica-gel by using 2percent EtOAc:hexane to obtain the desired product as a liquid (1.0 g, 65percent).
65%
Stage #1: With lithium diisopropyl amide In tetrahydrofuran at -78℃; for 0.75 h;
Stage #2: at -78 - 20℃; for 6 h;
A solution of O1-tert-butyl O4-ethyl piperidine-1,4-dicarboxylate (1.5 g, 5.84 mmol) in THF (25 mL) was cooled to -78° C. followed by dropwise addition of LDA (1.80 M in THF, 6.5 mL, 11.68 mmol) at -78° C.
The resulting mixture was stirred at -78° C. for 45 min followed by addition of methyl iodide (1.2 mL, 17.52 mmol).
The temperature was slowly raised up to RT and left at RT for 6 h.
The reaction was cooled to 0° C. and quenched by the dropwise addition of saturated NH4Cl solution (50 mL).
The reaction was extracted with EtOAc (3*100 mL).
The combined organics were washed with brine, dried (Na2SO4), filtered and concentrated in vacuo.
Purification by chromatography on silica eluting with 2percent EtOAc in hexane gave i (1.0 g, 65percent).
60%
Stage #1: With n-butyllithium; N-ethyl-N,N-diisopropylamine In tetrahydrofuran; hexane at -70℃; for 1.25 h;
Stage #2: at -70 - 20℃;
Method V: 1-tert-butyl 4-ethyl 4-methylpiperidine-1,4-dicarboxylate
Butyllithium 2.5 M in hexanes (15 ml, 37.5 mmol) was added dropwise over 15 minutes to an ice cold solution of diisopropylamine (5.35 ml, 37.5 mmol) in tetrahydrofuran (200 ml).
The solution was stirred at 0° C. for 15 minutes, then cooled to -70° C. A solution of 1-tert-butyl 4-Ethyl piperidine-1,4-dicarboxylate (9.0 g, 35 mmol) in tetrahydrofuran (30 ml) was added dropwise over 15 minutes.
The reaction mixture was stirred at -70° C. for a further 1 hour.
A solution of methyl iodide (3.2 ml, 52 mmol) in tetrahydrofuran (30 ml) was added dropwise over 15 minutes.
The reaction mixture was stirred at -70° C. for a further 2 hours and then allowed to warm up to room temperature overnight.
The reaction mixture was partitioned between EtOAc and a saturated solution of ammonium chloride.
The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo.
The residue was purified on silica gel by flash column chromatography to afford the desired compound (5.7 g, 60percent yield).
1H NMR (CDCl3, 400 MHz) δ 1.21 (3H, s), 1.28 (3H, t), 1.32-1.42 (2H, m), 1.47 (9H, s), 2.08 (2H, dt), 2.95-3.03 (2H, m), 3.79 (2H, dt), 4.18 (2H, q).
52%
Stage #1: With lithium diisopropyl amide In tetrahydrofuran at -78℃; for 1 h;
Stage #2: for 1 h;
To a stirred solution ofN-Boc-ethylisonipecotate 17 (503.4 mg, 1.96 mmols) in dry THF(10.0 mL), cooled at -78 °C, freshly prepared solution of lithiumdiisopropyl amide (0.5 M in THF,4.70 mL) was added. After stirring the reaction mixture for 1 h, methyl iodide(0.2 mL, 2.94 mmols) was added and the stirring continued for another hourbefore the reaction mixture was quenched with saturated aqueous NH4Clsolution. The reaction mass was extracted with ethylacetate and the combinedorganic layer was dried over anhydrous Na2SO4. Thesolvent was removed under reduced pressure and the crude product was purifiedby silica gel column chromatography to obtain the above titled compound 18 (280.5 mg) as gummy liquid in 52percentyield. 1H - NMR (CDCl3): d 4.16 (q, J= 7.1 Hz, 2H), 3.88-3.72 (m, 2H), 3.10-2.92 (m, 2H), 2.13-2.02 (m, 2 H),1.42 (s,9H), 1.45-1.32 (m, 2H), 1.25 (t, J =7.1 Hz, 3H) , 1.19 (s, 3H ).Mass (m/z): 272.4 (M+H)+
17.7 g
Stage #1: With lithium diisopropyl amide In tetrahydrofuran; hexane at -60 - -20℃; for 0.833333 h; Inert atmosphere
Stage #2: at -50℃; for 0.833333 h;
To a -60 °C solution of 1-(tert-butyl) 4-ethyl piperidine-1,4-dicarboxylate (15.52 g,60.31 mmol) in THF (100 ml) was added LDA(2 M solution in THF/Hex, 45.00 mL, 90.00 mmol)dropwise under nitrogen atmosphere. The resulting mixture was allowed to warm to -20 °C and stirred for 50 mm. The mixture was cooled to -50 °C, and a solution of CH3I (8.56 g, 60.31 mmol) in THF (20 mL) was added dropwise. The resulting mixture was stirred for 50 mm at this temperature. The reaction mixture was carefully quenched with sat. aq. NH4C1 (80 mL), extractedwith EA (100 mL, 50 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 1-(tert-butyl) 4-ethyl 4-methylpiperidine-1,4-dicarboxylate (17.70 g) which was used without any further purification. MS: m/z 216 (M+H-56) .

Reference: [1] Patent: WO2015/86527, 2015, A1, . Location in patent: Page/Page column 113; 114
[2] Patent: WO2015/86525, 2015, A1, . Location in patent: Page/Page column 117
[3] Patent: WO2008/121687, 2008, A2, . Location in patent: Page/Page column 43; 89; 94
[4] Patent: WO2006/83003, 2006, A1, . Location in patent: Page/Page column 36-37
[5] Journal of Medicinal Chemistry, 2017, vol. 60, # 11, p. 4680 - 4692
[6] ACS Medicinal Chemistry Letters, 2013, vol. 4, # 2, p. 244 - 248
[7] Patent: WO2008/89201, 2008, A2, . Location in patent: Page/Page column 233
[8] Patent: US2015/152065, 2015, A1, . Location in patent: Paragraph 0581
[9] Patent: US2012/88750, 2012, A1, . Location in patent: Page/Page column 17; 18
[10] Patent: US2013/252938, 2013, A1, . Location in patent: Paragraph 0465
[11] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 24, p. 6598 - 6603
[12] Patent: US2010/137305, 2010, A1, . Location in patent: Page/Page column 36
[13] European Journal of Medicinal Chemistry, 2015, vol. 103, p. 289 - 301
[14] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 14, p. 3675 - 3678
[15] Patent: US6083949, 2000, A,
[16] Patent: US5717100, 1998, A,
[17] Organic Process Research and Development, 2009, vol. 13, # 6, p. 1145 - 1155
[18] Patent: EP854870, 2009, B1, . Location in patent: Page/Page column 41-42
[19] Patent: EP2511275, 2012, A1, . Location in patent: Page/Page column 15
[20] Patent: WO2012/140020, 2012, A1, . Location in patent: Page/Page column 31-32
[21] Patent: WO2018/172984, 2018, A1, . Location in patent: Paragraph 61
  • 6
  • [ 74-88-4 ]
  • [ 189442-87-3 ]
Reference: [1] Patent: WO2005/30209, 2005, A1, . Location in patent: Page/Page column 46
[2] Patent: WO2008/11499, 2008, A1, . Location in patent: Page/Page column 38
  • 7
  • [ 24424-99-5 ]
  • [ 189442-87-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2017, vol. 60, # 11, p. 4680 - 4692
[2] Patent: WO2008/121687, 2008, A2,
  • 8
  • [ 498-94-2 ]
  • [ 189442-87-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2017, vol. 60, # 11, p. 4680 - 4692
  • 9
  • [ 84358-13-4 ]
  • [ 189442-87-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2017, vol. 60, # 11, p. 4680 - 4692
  • 10
  • [ 1126-09-6 ]
  • [ 189442-87-3 ]
Reference: [1] Patent: WO2008/121687, 2008, A2,
  • 11
  • [ 189442-87-3 ]
  • [ 189442-92-0 ]
Reference: [1] Patent: US6140333, 2000, A,
[2] Patent: WO2018/172984, 2018, A1,
  • 12
  • [ 189442-87-3 ]
  • [ 236406-22-7 ]
Reference: [1] European Journal of Medicinal Chemistry, 2015, vol. 103, p. 289 - 301
[2] Patent: US6140333, 2000, A,
  • 13
  • [ 189442-87-3 ]
  • [ 297172-16-8 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2013, vol. 4, # 2, p. 244 - 248
[2] Patent: WO2013/96744, 2013, A1,
  • 14
  • [ 189442-87-3 ]
  • [ 225240-71-1 ]
YieldReaction ConditionsOperation in experiment
99% With hydrogenchloride In 1,4-dioxane; ethanol at 20℃; for 6 h; 4M Solution of hydrogen chloride in 1,4-dioxane (3 mL) was added to a solution of 1- tert-butyl 4-ethyl 4-methylpiperidine-1,4-dicarboxylate (0.34 g, 1.25 mmol) in ethanol (4 mL) and the resulting mixture was stirred for 6 hours at room temperature. The solvents were evaporated and the residue was treated with diethyl ether, filtered and washed with diethyl ether to yield the hydrochloride salt of the title compound (0.3 g,99percent) as a white solid.LRMS (mlz): 172 (M+1)+.
59.6% With hydrogenchloride In 1,4-dioxane at 0 - 20℃; for 18 h; Inert atmosphere To a solution of Intermediate 25 ( 11.0 g, 40.5 mmol) dissolved in 1,4-Dioxane (30.0 mL) at 0-5°C was added HC1 (15.2 mL, 4 M in 1,4-dioxane) the mixture was allowed to warm to r.t. and stirred for 18h. The reaction mixture was concentrated in vacuo and residue washed with diethyl ether, yielding the title compound as an orange solid (5.02 g, 59.6percent). 1H NMR (DMSO-d6) δ: 9.00 (m, 1 H), 4.14 (q, J 6.8 Hz, 2 H), 3.16 (m, 2 H), 2.82 (m, 2 H), 2.08 (d, J 14.4 Hz, 2 H), 1.65 (m, 2 H), 1.22 (m, 6 H).
59.6% With hydrogenchloride In 1,4-dioxane at 0 - 20℃; for 18 h; To a solution of Intermediate 37 (11.0 g, 40.5 mmol) dissolved in 1 ,4-dioxane (30.0 mL) at 0-5°C was added HC1 (15.2 mL, 4 M in 1,4-dioxane). The mixture was allowed to warm to r.t. and stirred for 1 8h. The reaction mixture was concentrated in vacuo and residue washed with diethyl ether, yielding the title compound as an orange solid (5.02 g, 59.6percent). 1H NMR (DMSO-d6) ö: 9.00 (m, 1 H), 4.14 (q, J 6.8 Hz, 2 H), 3.16 (m, 2 H), 2.82 (m, 2 H), 2.08 (d, J 14.4 Hz, 2 H), 1.65 (m, 2 H), 1.22 (m, 6 H).
0.90 g With hydrogenchloride In 1,4-dioxane at 20℃; for 0.5 h; Ethyl 4-methylpiperidine-4-carboxylate hydrochloride (ii)
To an ice-cold solution of i (1 g, 3.68 mmol) in 1,4-dioxane (10 mL) was added HCl-1,4-dioxane (4.0 M, 15 mL) solution and stirred at RT for 30 min.
The solvent was evaporated to obtain ii (0.90 g). MS: 172.16 [M+H]+.

Reference: [1] Patent: WO2015/86693, 2015, A1, . Location in patent: Page/Page column 121
[2] Patent: WO2015/86527, 2015, A1, . Location in patent: Page/Page column 114
[3] Patent: WO2015/86525, 2015, A1, . Location in patent: Page/Page column 117; 118
[4] Patent: WO2006/83003, 2006, A1, . Location in patent: Page/Page column 37
[5] Patent: WO2006/59945, 2006, A1, . Location in patent: Page/Page column 69
[6] Patent: US2012/88750, 2012, A1, . Location in patent: Page/Page column 17; 18
[7] Patent: US2013/252938, 2013, A1, . Location in patent: Paragraph 0466
[8] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 24, p. 6598 - 6603
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 189442-87-3 ]

Amides

Chemical Structure| 188792-70-3

[ 188792-70-3 ]

Ethyl 1-Boc-4-ethyl-4-piperidine carboxylate

Similarity: 1.00

Chemical Structure| 1022128-75-1

[ 1022128-75-1 ]

Ethyl 1-Boc-4-isopropyl-4-piperidinecarboxylate

Similarity: 1.00

Chemical Structure| 867009-56-1

[ 867009-56-1 ]

1-tert-Butyl 4-ethyl 4-(2-ethoxy-2-oxoethyl)piperidine-1,4-dicarboxylate

Similarity: 1.00

Chemical Structure| 1033819-09-8

[ 1033819-09-8 ]

1-tert-Butyl 4-ethyl 4-propylpiperidine-1,4-dicarboxylate

Similarity: 1.00

Chemical Structure| 1423037-40-4

[ 1423037-40-4 ]

Methyl 1-BOC-4-(2-ethoxy-2-oxoethyl)piperidine-4-carboxylate

Similarity: 1.00

Esters

Chemical Structure| 188792-70-3

[ 188792-70-3 ]

Ethyl 1-Boc-4-ethyl-4-piperidine carboxylate

Similarity: 1.00

Chemical Structure| 1022128-75-1

[ 1022128-75-1 ]

Ethyl 1-Boc-4-isopropyl-4-piperidinecarboxylate

Similarity: 1.00

Chemical Structure| 867009-56-1

[ 867009-56-1 ]

1-tert-Butyl 4-ethyl 4-(2-ethoxy-2-oxoethyl)piperidine-1,4-dicarboxylate

Similarity: 1.00

Chemical Structure| 1033819-09-8

[ 1033819-09-8 ]

1-tert-Butyl 4-ethyl 4-propylpiperidine-1,4-dicarboxylate

Similarity: 1.00

Chemical Structure| 1423037-40-4

[ 1423037-40-4 ]

Methyl 1-BOC-4-(2-ethoxy-2-oxoethyl)piperidine-4-carboxylate

Similarity: 1.00

Related Parent Nucleus of
[ 189442-87-3 ]

Piperidines

Chemical Structure| 188792-70-3

[ 188792-70-3 ]

Ethyl 1-Boc-4-ethyl-4-piperidine carboxylate

Similarity: 1.00

Chemical Structure| 1022128-75-1

[ 1022128-75-1 ]

Ethyl 1-Boc-4-isopropyl-4-piperidinecarboxylate

Similarity: 1.00

Chemical Structure| 867009-56-1

[ 867009-56-1 ]

1-tert-Butyl 4-ethyl 4-(2-ethoxy-2-oxoethyl)piperidine-1,4-dicarboxylate

Similarity: 1.00

Chemical Structure| 1033819-09-8

[ 1033819-09-8 ]

1-tert-Butyl 4-ethyl 4-propylpiperidine-1,4-dicarboxylate

Similarity: 1.00

Chemical Structure| 1423037-40-4

[ 1423037-40-4 ]

Methyl 1-BOC-4-(2-ethoxy-2-oxoethyl)piperidine-4-carboxylate

Similarity: 1.00